Before revision: The ASPREE-XT study is designed to determine whether there are long-lasting effects of an average of 4 – 5 years of treatment with daily low-dose aspirin, with outcome measures including cancer mortality.
After revision: The ASPREE-XT study is designed to determine whether there are long-lasting effects of an average of four – five years of treatment with daily low-dose aspirin, with outcome measures including cancer mortality.